Dermapharm Holding SE (LON:0A5J)
London · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 1.68B +11.7% |
| Revenue (ttm) | 1.03B -1.4% |
| Net Income | 125.92M +39.2% |
| EPS | 2.34 +39.3% |
| Shares Out | n/a |
| PE Ratio | 13.36 |
| Forward PE | 13.57 |
| Dividend | 0.77 (2.22%) |
| Ex-Dividend Date | Jun 29, 2026 |
| Volume | 2,337 |
| Open | 41.58 |
| Previous Close | 40.48 |
| Day's Range | 39.98 - 40.55 |
| 52-Week Range | 31.85 - 51.70 |
| Beta | 0.85 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company a... [Read more]
Financial Performance
In 2025, Dermapharm Holding SE's revenue was 1.18 billion, a decrease of -1.43% compared to the previous year's 1.20 billion. Earnings were 132.41 million, an increase of 16.37%.
Financial numbers in EUR Financial StatementsNews
Dermapharm Holding SE Earnings Call Transcript: Q1 2026
Q1 2026 delivered 1.1% revenue growth and a 7.5% rise in adjusted EBITDA, with margin expansion and strong free cash flow. All segments contributed, Mucos integration advanced, and the share buyback reduced free float to just above 10%.
Dermapharm Holding SE Slides: Q1 2026
Dermapharm Holding SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Dermapharm Holding SE Quarterly report: Q1 2026
Dermapharm Holding SE has published its Q1 2026 quarterly earnings report on May 13, 2026.
Dermapharm Holding SE Earnings Call Transcript: Q4 2025
Revenue and adjusted EBITDA for 2025 met guidance, with margin improvements and strong cash flow. Growth is expected in 2026 from M&A, branded products, and international expansion, while restructuring and portfolio optimization continue to drive efficiency.
Dermapharm Holding SE Annual report: Q4 2025
Dermapharm Holding SE has published its Q4 2025 annual report on March 31, 2026.
Dermapharm Holding SE Annual report: Q4 2025
Dermapharm Holding SE has published its Q4 2025 annual report on March 31, 2026.
Dermapharm Holding SE Earnings release: Q4 2025
Dermapharm Holding SE released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Dermapharm Holding SE Slides: Q4 2025
Dermapharm Holding SE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 31, 2026.
Dermapharm Holding SE Earnings Call Transcript: Q3 2025
Branded pharmaceuticals drove growth in Q3 2025, with strong international and Alargo Pharma performance. Portfolio optimization and restructuring improved margins, while guidance for full-year revenue and EBITDA is expected to be met, supported by seasonal strength in Q4.
Dermapharm Holding SE Quarterly report: Q3 2025
Dermapharm Holding SE has published its Q3 2025 quarterly earnings report on November 13, 2025.
Dermapharm Holding SE Slides: Q3 2025
Dermapharm Holding SE has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 13, 2025.
Dermapharm Holding SE Quarterly report: Q2 2025
Dermapharm Holding SE has published its Q2 2025 quarterly earnings report on August 26, 2025.
Dermapharm Holding SE Slides: Q2 2025
Dermapharm Holding SE has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 26, 2025.